WolfeMMLichtensteinDRSinghG. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med1999;340:1888–99.
2.
BombardierCLaineLReicinAShapiroDBurgos-VargasRDavisBComparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med2000;343: 1520–8.
3.
SimonLSWeaverALGrahamDYKivitzAJLipskyPEHubbardRCAnti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. JAMA1999;282:1921–8.
4.
FeldmanMMcMahonAT. Do cyclooxygenase–2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity?Ann Intern Med2000;132:134–43.
5.
HermanRJ. Drug interactions and the statins. CMAJ1999;161:1281–6.
6.
LetwinSRConstableKOldringB. Digoxin toxicity associated with clarithromycin — A reminder (letter). Can J Hosp Pharm1998;51:273.
7.
Hernandez-DiazSRodriguezLAG. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation. Arch Intern Med2000;160:2093–9.
8.
HuntRThomsonABR. Canadian Helicobacter pylori consensus conference. Can J Gastroenterol1998;12:31–41.
9.
Product monograph. Celebrex (celecoxib). Chicago: GD Searle, December 1999.
10.
SilversteinFEFaichGGoldsteinJLSimonLSPincusTWheltonAGastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. JAMA2000;284: 1247–55.
11.
LichtensteinDRWolfeMM. COX-2-selective NSAIDs. New and improved? JAMA2000;284:1297–9.
12.
NaranjoCABustoUSellersEMSandorPRuizIRobertsEAA method for estimating the probability of adverse reactions. Clin Pharmacol Ther1981;30:239–45.
